IL260789B - מפרקי קולטן אסטרוגן סלקטיביים ושימושים בהם - Google Patents
מפרקי קולטן אסטרוגן סלקטיביים ושימושים בהםInfo
- Publication number
- IL260789B IL260789B IL260789A IL26078918A IL260789B IL 260789 B IL260789 B IL 260789B IL 260789 A IL260789 A IL 260789A IL 26078918 A IL26078918 A IL 26078918A IL 260789 B IL260789 B IL 260789B
- Authority
- IL
- Israel
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor degraders
- degraders
- selective
- Prior art date
Links
- 229940125641 estrogen receptor degrader Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291921P | 2016-02-05 | 2016-02-05 | |
PCT/US2017/016452 WO2017136688A1 (en) | 2016-02-05 | 2017-02-03 | Selective estrogen receptor degraders and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL260789B true IL260789B (he) | 2021-03-25 |
Family
ID=59501091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL260789A IL260789B (he) | 2016-02-05 | 2018-07-26 | מפרקי קולטן אסטרוגן סלקטיביים ושימושים בהם |
Country Status (16)
Country | Link |
---|---|
US (4) | US10647724B2 (he) |
EP (1) | EP3411034B1 (he) |
JP (1) | JP6905539B2 (he) |
KR (1) | KR102479822B1 (he) |
CN (2) | CN113004273A (he) |
AU (1) | AU2017213614B2 (he) |
BR (1) | BR112018015419B1 (he) |
CA (1) | CA3012078C (he) |
DK (1) | DK3411034T3 (he) |
ES (1) | ES2842579T3 (he) |
IL (1) | IL260789B (he) |
MX (1) | MX2018009496A (he) |
NZ (1) | NZ744516A (he) |
RU (1) | RU2734501C2 (he) |
WO (1) | WO2017136688A1 (he) |
ZA (1) | ZA201805573B (he) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017007662B1 (pt) | 2014-12-18 | 2021-11-03 | F. Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto |
CN107428758B (zh) * | 2015-11-12 | 2020-08-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
MX2018009496A (es) * | 2016-02-05 | 2018-12-11 | Inventisbio Inc | Degradadores selectivos del receptor de estrogeno y sus usos. |
JP6733872B2 (ja) * | 2016-02-26 | 2020-08-05 | ロンザ ウォーカーズヴィル,インコーポレーテッド | 肝細胞を寄せ集める方法 |
CA3017388C (en) | 2016-04-01 | 2024-03-12 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
WO2017216279A1 (en) * | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | Heteroaryl estrogen receptor modulators and uses thereof |
CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
TW202000663A (zh) | 2018-02-28 | 2020-01-01 | 美商費洛醫療公司 | 化合物及使用方法 |
CN110343101B (zh) * | 2018-04-04 | 2022-07-12 | 青岛福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
UA128114C2 (uk) | 2018-06-21 | 2024-04-10 | Ф. Хоффманн-Ля Рош Аг | Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування |
WO2020037203A2 (en) | 2018-08-17 | 2020-02-20 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
JP7448541B2 (ja) * | 2018-12-24 | 2024-03-12 | インベンティスバイオ カンパニー リミテッド | 選択的エストロゲン受容体分解剤の新規な塩 |
US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
WO2020238733A1 (zh) * | 2019-05-24 | 2020-12-03 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
EP3993787A4 (en) | 2019-08-06 | 2023-07-12 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS |
WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
WO2024042163A1 (en) * | 2022-08-25 | 2024-02-29 | Sanofi | Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2473441A1 (en) | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
WO2004091488A2 (en) * | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
SG184755A1 (en) * | 2004-03-15 | 2012-10-30 | Ptc Therapeutics Inc | Carboline derivatives useful in the inhibition of angiogenesis |
TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
WO2010138685A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
WO2011050162A1 (en) * | 2009-10-22 | 2011-04-28 | Polymedix, Inc. | Processes for preparing a polymeric compound |
ES2627692T3 (es) * | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
TWI560172B (en) * | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
WO2013090829A1 (en) * | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
US20140122109A1 (en) * | 2012-10-29 | 2014-05-01 | Consuli, Inc. | Clinical diagnosis objects interaction |
CA2899969A1 (en) | 2013-03-14 | 2014-09-25 | Seragon Pharmaceuticals, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
WO2014191726A1 (en) * | 2013-05-28 | 2014-12-04 | Astrazeneca Ab | Chemical compounds |
RU2015152171A (ru) * | 2013-06-19 | 2017-07-25 | Серагон Фармасьютикалз, Инк. | Азетидиновые модуляторы эстрогеновых рецепторов и их применения |
JP2017509631A (ja) | 2014-03-13 | 2017-04-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体突然変異体を調節する方法及び組成物 |
TW201625244A (zh) | 2014-06-12 | 2016-07-16 | 小野藥品工業股份有限公司 | 壓力性疾病之預防及/或治療用醫藥 |
BR112017007662B1 (pt) * | 2014-12-18 | 2021-11-03 | F. Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto |
US10087191B2 (en) | 2015-06-16 | 2018-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
UA122346C2 (uk) * | 2015-10-01 | 2020-10-26 | Олема Фармасьютикалз, Інк. | ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ |
CN107428758B (zh) * | 2015-11-12 | 2020-08-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
MX2018009496A (es) * | 2016-02-05 | 2018-12-11 | Inventisbio Inc | Degradadores selectivos del receptor de estrogeno y sus usos. |
CA3017388C (en) | 2016-04-01 | 2024-03-12 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
WO2017216279A1 (en) | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | Heteroaryl estrogen receptor modulators and uses thereof |
JP2019521983A (ja) | 2016-06-16 | 2019-08-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロ−ピリド[3,4−b]インドールエストロゲン受容体モジュレーター及びその使用 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
CN110139863B (zh) | 2016-10-28 | 2022-02-18 | 罗欣健康科技发展(北京)有限公司 | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 |
WO2018130124A1 (zh) | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
DK3494116T3 (da) | 2017-01-30 | 2020-01-27 | Astrazeneca | Østrogenreceptormodulatorer |
JP7448541B2 (ja) * | 2018-12-24 | 2024-03-12 | インベンティスバイオ カンパニー リミテッド | 選択的エストロゲン受容体分解剤の新規な塩 |
-
2017
- 2017-02-03 MX MX2018009496A patent/MX2018009496A/es unknown
- 2017-02-03 RU RU2018128318A patent/RU2734501C2/ru active
- 2017-02-03 AU AU2017213614A patent/AU2017213614B2/en active Active
- 2017-02-03 EP EP17748247.8A patent/EP3411034B1/en active Active
- 2017-02-03 ES ES17748247T patent/ES2842579T3/es active Active
- 2017-02-03 KR KR1020187025594A patent/KR102479822B1/ko active IP Right Grant
- 2017-02-03 CN CN202110236070.7A patent/CN113004273A/zh active Pending
- 2017-02-03 NZ NZ744516A patent/NZ744516A/en unknown
- 2017-02-03 US US16/073,673 patent/US10647724B2/en active Active
- 2017-02-03 JP JP2018560447A patent/JP6905539B2/ja active Active
- 2017-02-03 WO PCT/US2017/016452 patent/WO2017136688A1/en active Application Filing
- 2017-02-03 DK DK17748247.8T patent/DK3411034T3/da active
- 2017-02-03 CA CA3012078A patent/CA3012078C/en active Active
- 2017-02-03 BR BR112018015419-9A patent/BR112018015419B1/pt active IP Right Grant
- 2017-02-03 CN CN201780008535.5A patent/CN109362222B/zh active Active
-
2018
- 2018-07-26 IL IL260789A patent/IL260789B/he active IP Right Grant
- 2018-08-21 ZA ZA2018/05573A patent/ZA201805573B/en unknown
-
2019
- 2019-10-17 US US16/655,689 patent/US11014936B2/en active Active
-
2021
- 2021-04-27 US US17/241,722 patent/US20210253592A1/en not_active Abandoned
-
2023
- 2023-07-11 US US18/220,484 patent/US20240043442A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102479822B1 (ko) | 2022-12-21 |
CN109362222B (zh) | 2021-03-19 |
NZ744516A (en) | 2024-05-31 |
RU2018128318A (ru) | 2020-03-05 |
BR112018015419B1 (pt) | 2024-01-30 |
US20200040001A1 (en) | 2020-02-06 |
EP3411034A4 (en) | 2019-08-28 |
US11014936B2 (en) | 2021-05-25 |
BR112018015419A2 (pt) | 2018-12-18 |
EP3411034A1 (en) | 2018-12-12 |
DK3411034T3 (da) | 2021-01-11 |
WO2017136688A1 (en) | 2017-08-10 |
CN113004273A (zh) | 2021-06-22 |
KR20180104161A (ko) | 2018-09-19 |
ES2842579T3 (es) | 2021-07-14 |
US20210253592A1 (en) | 2021-08-19 |
AU2017213614B2 (en) | 2022-09-01 |
JP6905539B2 (ja) | 2021-07-21 |
RU2734501C2 (ru) | 2020-10-19 |
CN109362222A (zh) | 2019-02-19 |
AU2017213614A1 (en) | 2018-08-09 |
JP2019504890A (ja) | 2019-02-21 |
RU2018128318A3 (he) | 2020-04-02 |
CA3012078C (en) | 2024-01-30 |
EP3411034B1 (en) | 2020-11-25 |
US10647724B2 (en) | 2020-05-12 |
ZA201805573B (en) | 2020-12-23 |
MX2018009496A (es) | 2018-12-11 |
US20200048250A1 (en) | 2020-02-13 |
US20240043442A1 (en) | 2024-02-08 |
CA3012078A1 (en) | 2017-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201805573B (en) | Selective estrogen receptor degraders and uses thereof | |
IL284424B (he) | תולדות טטראהידרונפתלן וטטראהידרואיזוקווינולין כמפרקי קולטן אסטרוגן | |
HK1247199A1 (zh) | 雌激素受體調節劑及其用途 | |
IL266353A (he) | סטרואידים ותצמידי חלבון שלהם | |
HK1248683A1 (zh) | 雜環雌激素受體調節劑及其用途 | |
IL295598B2 (he) | מפרקי קולטן אסטרוגן סלקטיבי | |
HK1258851A1 (zh) | 四氫萘雌激素受體調節劑及其用途 | |
ZA201803422B (en) | Benzothiophene-based selective estrogen receptor downregulators | |
HK1258886A1 (zh) | T細胞受體及其用途 | |
IL279990B1 (he) | מפרקי קולטן אסטרוגן סלקטיבי |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |